Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Early CRP kinetics to predict long-term efficacy of first-line immune-checkpoint inhibition combination therapies in metastatic renal cell carcinoma: an updated multicentre real-world experience applying different CRP kinetics definitions.
Hoeh B, Garcia CC, Banek S, Klümper N, Cox A, Ellinger J, Schmucker P, Hahn O, Mattigk A, Zengerling F, Becker P, Erdmann K, Buerk BT, Flegar L, Huber J, Kalogirou C, Zeuschner P. Hoeh B, et al. Among authors: klumper n. Clin Transl Immunology. 2023 Oct 25;12(10):e1471. doi: 10.1002/cti2.1471. eCollection 2023. Clin Transl Immunology. 2023. PMID: 37899949 Free PMC article.
C-reactive protein flare-response predicts long-term efficacy to first-line anti-PD-1-based combination therapy in metastatic renal cell carcinoma.
Klümper N, Schmucker P, Hahn O, Höh B, Mattigk A, Banek S, Ellinger J, Heinzelbecker J, Sikic D, Eckstein M, Strauß A, Zengerling F, Hölzel M, Zeuschner P, Kalogirou C. Klümper N, et al. Clin Transl Immunology. 2021 Dec 6;10(12):e1358. doi: 10.1002/cti2.1358. eCollection 2021. Clin Transl Immunology. 2021. PMID: 34925829 Free PMC article.
Comparison of First-Line Anti-PD-1-Based Combination Therapies in Metastatic Renal-Cell Carcinoma: Real-World Experiences from a Retrospective, Multi-Institutional Cohort.
Hoeh B, Schmucker P, Klümper N, Hahn O, Zeuschner P, Banek S, Karakiewicz PI, Ellinger J, Heinzelbecker J, Hölzel M, Strauß A, Zengerling F, Mattigk A, Kalogirou C. Hoeh B, et al. Among authors: klumper n. Urol Int. 2022;106(11):1150-1157. doi: 10.1159/000521661. Epub 2022 Feb 14. Urol Int. 2022. PMID: 35158357
C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma.
Klümper N, Sikic D, Saal J, Büttner T, Goldschmidt F, Jarczyk J, Becker P, Zeuschner P, Weinke M, Kalogirou C, Breyer J, Burger M, Nuhn P, Tully K, Roghmann F, Bolenz C, Zengerling F, Wirtz RM, Muders M, Kristiansen G, Bald T, Ellinger J, Wullich B, Hölzel M, Hartmann A, Erben P, Ritter M, Eckstein M. Klümper N, et al. Eur J Cancer. 2022 May;167:13-22. doi: 10.1016/j.ejca.2022.02.022. Epub 2022 Mar 30. Eur J Cancer. 2022. PMID: 35366569 Free article.
Insights into Urologic Cancer.
Klümper N, Ellinger J. Klümper N, et al. Cancers (Basel). 2023 Jun 8;15(12):3108. doi: 10.3390/cancers15123108. Cancers (Basel). 2023. PMID: 37370718 Free PMC article.
78 results